FDA Approves RiVive Over-the-Counter Naloxone Nasal Spray For Opioid Overdose Reversal

The U.S Food and Drug Administration (FDA) approved RiVive an over-the-counter (OTC) 3 milligram naloxone nasal spray product for emergency use to treat a known or suspected opioid overdose. RiVive, manufactured by Harm Reduction Therapeutics, is the second OTC naloxone product approved by the FDA. The timeline for availability and the price of this nonprescription product will be determined by the manufacturer.

The FDA has taken a series of steps to help facilitate access to opioid overdose reversal products and to decrease unnecessary exposure to opioids and prevent new cases of addiction. The agency approved the first . . .